Type: report
Abstract: To elucidate the resistance mechanism of the KRAS inhibitor sotorasib, we conducted an exploratory study using sotorasib-resistant clones of the KRAS mutation-positive lung cancer cell lines H23 and H2122, which revealed two resistance mechanisms: 1) MET gene amplification and 2) EGFR abnormal activation dependent on suppression of PTPRR (Protein Tyrosine Phosphatase Receptor R) gene expression were identified. Mouse model studies using these resistant cells showed that the combination of MET or EGFR inhibitors was useful in overcoming resistance to sotorasib. In a retrospective study of patients with KRAS G12C mutation-positive lung cancer, the association between PTPRR protein expression and progression-free survival with sotorasib therapy was poor [hazard ratio 3.27] in the low-expression group.
Institution: Kindai University
Language: Japanese
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: green
OpenAlex ID: W7208184643
